BioArctic AB Share Price

Equities

BIOA B

SE0010323311

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 08:59:37 26/04/2024 pm IST 5-day change 1st Jan Change
197.5 SEK +1.96% Intraday chart for BioArctic AB +0.41% -26.25%

Financials

Sales 2024 * 502M 45.93M 3.83B Sales 2025 * 1.01B 92.34M 7.7B Capitalization 17.44B 1.59B 133B
Net income 2024 * 16M 1.46M 122M Net income 2025 * 454M 41.5M 3.46B EV / Sales 2024 * 33 x
Net cash position 2024 * 838M 76.56M 6.38B Net cash position 2025 * 1.17B 107M 8.95B EV / Sales 2025 * 16.1 x
P/E ratio 2024 *
993 x
P/E ratio 2025 *
38.5 x
Employees 88
Yield 2024 *
-
Yield 2025 *
-
Free-Float 44.12%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.96%
1 week+0.41%
Current month-8.31%
1 month-9.90%
3 months-12.30%
6 months-15.09%
Current year-26.25%
More quotes
1 week
175.00
Extreme 175
206.40
1 month
175.00
Extreme 175
235.80
Current year
175.00
Extreme 175
288.40
1 year
175.00
Extreme 175
392.00
3 years
66.70
Extreme 66.7
392.00
5 years
47.00
Extreme 47
392.00
10 years
20.40
Extreme 20.4
392.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 01/13/01
Founder 77 24/03/24
Founder 75 24/03/24
Members of the board TitleAgeSince
Chairman 70 01/17/01
Director/Board Member 58 01/23/01
Director/Board Member 56 -
More insiders
Date Price Change Volume
26/24/26 197.5 +1.96% 121,787
25/24/25 193.7 -0.92% 138,091
24/24/24 195.5 +3.77% 232,942
23/24/23 188.4 +2.06% 226,319
22/24/22 184.6 -6.15% 701,192

Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:59 pm IST

More quotes
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
197.5 SEK
Average target price
366.2 SEK
Spread / Average Target
+85.42%
Consensus
  1. Stock Market
  2. Equities
  3. BIOA B Stock